JP7007381B2 - 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド - Google Patents

細胞外クエン酸の取込みの阻害剤としてのスルホンアミド Download PDF

Info

Publication number
JP7007381B2
JP7007381B2 JP2019530714A JP2019530714A JP7007381B2 JP 7007381 B2 JP7007381 B2 JP 7007381B2 JP 2019530714 A JP2019530714 A JP 2019530714A JP 2019530714 A JP2019530714 A JP 2019530714A JP 7007381 B2 JP7007381 B2 JP 7007381B2
Authority
JP
Japan
Prior art keywords
compound
group
citric acid
substituted
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019530714A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500907A5 (enExample
JP2020500907A (ja
Inventor
ヨルク クレイ
シュテファン カウシュケ
アレクサンダー パウチ
ディーター ヴィーデンマイヤー
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020500907A publication Critical patent/JP2020500907A/ja
Publication of JP2020500907A5 publication Critical patent/JP2020500907A5/ja
Application granted granted Critical
Publication of JP7007381B2 publication Critical patent/JP7007381B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2019530714A 2016-12-09 2017-12-04 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド Active JP7007381B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16203086 2016-12-09
EP16203086.0 2016-12-09
PCT/EP2017/081359 WO2018104220A1 (en) 2016-12-09 2017-12-04 Sulfonamides as inhibitors of the uptake of extracellular citrate

Publications (3)

Publication Number Publication Date
JP2020500907A JP2020500907A (ja) 2020-01-16
JP2020500907A5 JP2020500907A5 (enExample) 2021-01-21
JP7007381B2 true JP7007381B2 (ja) 2022-01-24

Family

ID=57539116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019530714A Active JP7007381B2 (ja) 2016-12-09 2017-12-04 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド

Country Status (5)

Country Link
US (1) US10793522B2 (enExample)
EP (1) EP3551618B1 (enExample)
JP (1) JP7007381B2 (enExample)
CN (1) CN110325527B (enExample)
WO (1) WO2018104220A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺
GB2560713A (en) * 2017-03-20 2018-09-26 Eternygen Gmbh Inhibitor of citrate transporter
GB201918410D0 (en) * 2019-12-13 2020-01-29 Z Factor Ltd Compounds and their use for the treatment of alpha1-antitrypsin deficiency
GB202108523D0 (en) 2021-06-15 2021-07-28 Z Factor Ltd Compositions and their use for the treatment of alpha1-antitrypsin deficiency

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518451A (ja) 2005-12-12 2009-05-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体
WO2010080183A1 (en) 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
JP2013504533A (ja) 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー 糖尿病の処置に有用なｈｓｌインヒビター

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2178837A2 (en) 2007-07-26 2010-04-28 Comentis, Inc. Isophthalamide derivatives inhibiting beta-secretase activity
WO2013030138A1 (en) 2011-09-01 2013-03-07 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
TWI641595B (zh) * 2013-07-17 2018-11-21 日商大塚製藥股份有限公司 氰基三唑化合物類
CN110325527B (zh) 2016-12-09 2022-08-09 勃林格殷格翰国际有限公司 作为细胞外柠檬酸盐摄取的抑制剂的磺酰胺

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009518451A (ja) 2005-12-12 2009-05-07 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ キナーゼ阻害薬として活性な置換ピラゾロ［４，３−ｃ］ピリジン誘導体
WO2010080183A1 (en) 2009-01-08 2010-07-15 The Trustees Of Columbia University In The City Of New York Potent non-urea inhibitors of soluble epoxide hydrolase
JP2013504533A (ja) 2009-09-11 2013-02-07 エフ．ホフマン−ラ ロシュ アーゲー 糖尿病の処置に有用なｈｓｌインヒビター

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUARD, K. et al.，Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family，Journal of Medicinal Chemistry，2016年，59(3)，pp. 1165-1175

Also Published As

Publication number Publication date
WO2018104220A1 (en) 2018-06-14
EP3551618B1 (en) 2020-09-16
US10793522B2 (en) 2020-10-06
EP3551618A1 (en) 2019-10-16
CN110325527B (zh) 2022-08-09
CN110325527A (zh) 2019-10-11
JP2020500907A (ja) 2020-01-16
US20200062708A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
JP7658014B2 (ja) ピロリジン化合物
EP3630755B1 (en) 5-methyl-1,3,4-oxadiazol-2-yl compounds
CA3084694A1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
KR20190096421A (ko) Oga 억제제로서의 n-[4-플루오로-5-[[(2s,4s)-2-메틸-4-[(5-메틸-1,2,4-옥사디아졸-3-일)메톡시]-1-피페리딜]메틸]티아졸-2-일]아세트아미드
NO323952B1 (no) Substituerte indoler for modulering av NFκB-aktivitet, fremgangsmate for fremstilling, legemiddel omfattende disse, deres anvendelse og en fremgangsmate for fremstilling av et legemiddel.
JP2002510328A (ja) ビトロネクチン受容体アンタゴニスト
US9000182B2 (en) 2H-imidazol-4-amine compounds and their use as BACE inhibitors
US9000185B2 (en) Cycloalkyl ether compounds and their use as BACE inhibitors
US9000184B2 (en) Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors
UA128374C2 (uk) Гетероароматичні сполуки як інгібітори ваніну
JP2020500907A (ja) 細胞外クエン酸の取込みの阻害剤としてのスルホンアミド
CN114641466B (zh) 磺酰脲衍生物及其用途
AU2008320718A1 (en) Indol-2-one derivatives disubstituted in the 3-position, preparation thereof and therapeutic use thereof
KR20150064736A (ko) 아자인돌린
TWI258469B (en) Aryl-substituted alicyclic compounds and pharmaceutical composition containing the same
JP2007534616A (ja) アセチルコリンエステラーゼの阻害薬としてのタクリン誘導体
US20030130325A1 (en) Substituted tryptophan derivatives
TW200825056A (en) New compounds
WO2024026262A1 (en) Substituted pyrazolyl-pyridinyl compounds as ligand directed degraders of irak3
US20040006137A1 (en) Asymmetric synthesis of amino-pyrrolidinones and a crystalline, free-base amino-pyrrolidinone
EP4630114A1 (en) New cyanopyridine khk inhibitor compounds
TW202317093A (zh) 具有hiv複製抑制作用之縮合雜環衍生物
NZ754849B2 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
JPWO2000059913A1 (ja) 新規チアゾロベンゾイミダゾール誘導体
TW201221127A (en) Sulfamide derivatives having NPY Y5 receptor antagonistic activity

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201203

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211208

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220106

R150 Certificate of patent or registration of utility model

Ref document number: 7007381

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250